Senior Product Manager, Cala Health
Upstream
$160-190k
Bioelectronic medicine for chronic disease
Job no longer available
Bioelectronic medicine for chronic disease
101-200 employees
Job no longer available
$160-190k
101-200 employees
Company mission
To transform the standard of care for chronic disease with non-invasive wearable neuromodulation therapies.
Jump to section
Company mission
To transform the standard of care for chronic disease with non-invasive wearable neuromodulation therapies.
Our take
Essential Tremor is the most prevalent movement disorder in the world, with up to 5% of the global population affected by it. And yet, there were previously only two treatments: ongoing prescription drugs, which have side effects of drowsiness and nausea; or invasive surgery, which is costly and has risk of serious side effects.
Cala have developed a pioneering non-invasive treatment, which uses electrical stimulation from wearable device (it looks like a simple wristwatch) that monitors personal tremor levels and adapts its treatment to suit each patient. It is a world-leader in its field, and has revolutionized treatment for the 7 to 10 million Americans suffering from Essential Tremor.
With $50 million in funding awarded in 2025, Cala will accelerate its sales and marketing efforts and will continue to develop its technology to treat the symptoms of Parkinson's disease.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 7 rounds)
Apr 2026
$50m
GROWTH EQUITY VC
Oct 2025
$50m
LATE VC
Total funding: $298.3m
This company has top investors
Leadership
Kate Rosenbluth
(Founder, President & Chief Innovation Officer)Formerly a Consultant at Genentech, Scientist in Residence at Brainlab and Lecturer at Stanford.